CYTOCHROME P450 17A1 STRUCTURES WITH PROSTATE CANCER DRUGS ABIRATERONE AND TOK-001

Cytochrome P450 17A1 (P450c17) catalyzes the biosynthesis of androgens in humans(1). Since prostate cancer cells proliferate in response to androgen steroids(2,3), CYP17A1 inhibition is a new strategy to prevent androgen synthesis and treat lethal metastatic castration-resistant prostate cancer(4),...

Descripción completa

Detalles Bibliográficos
Autores principales: DeVore, Natasha M., Scott, Emily E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271139/
https://www.ncbi.nlm.nih.gov/pubmed/22266943
http://dx.doi.org/10.1038/nature10743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271139/
https://www.ncbi.nlm.nih.gov/pubmed/22266943
http://dx.doi.org/10.1038/nature10743

Ejemplares similares